BioSpace News Archive

VYNE Therapeutics Inc. announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for one-on-one meetings.

PharmAbcine Inc. announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ ., USA), to initiate a Phase I combination trial of PMC-309, a novel anti-VISTA (V-domain Ig suppressor of T cell activation) antibody, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy.

Serenus.AI will present its work for the development of an AI-based Personalized CDSS for the Treatment of Chronic Lymphocytic Leukemia (CLL), at the 2022 annual ASH meeting.

Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (rtCGM), announced today its partnership with Green Shield and The Health Depot digital pharmacy to provide Green Shield plan members with convenient access to the Dexcom G6 rtCGM System combined with virtual diabetes coaching support.

Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients.

RF Medical Co., Ltd. is a premier Korean-based medical company serving the healthcare industry for almost two decades. Recently, FDA cleared RF Medical’s patented MYGEN™ M-3004 generator and MYOBLATE™ radiofrequency ablation system.

Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company’s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company’s vice president of global finance, as its interim chief financial officer and treasurer, effective upon Mr. Rossi’s resignation.

Nuheara Limited is pleased to announce a major expansion of its US retail footprint, from circa 300 points of sale currently to circa 4,600 over the coming months, with US FDA cleared self-fit hearing aids now being manufactured to fulfill initial orders from Best Buy and other US retail customers.

TC BioPharm today announced its financial results for the first half ended June 30, 2022 and provided a shareholder update.

Kiyatec Inc. announced a closing of its Series C funding round totaling US$18 million from new and existing investors.